


of hydrogen and C₁₋₄-alkyl; or,

R¹ and R² together with the carbon atom to which they are bound form an optionally substituted cyclopentyl, cyclohexyl, cycloheptyl or decahydronaphthalenyl ring;

and

N-substituted amino acids of the general formula IIb



wherein n and R¹ are as defined above;

X³ and X⁶ are each independently selected from the group consisting of amino acids having hydrophobic side chains and amino acids having hydrophobic N-substituents;


X⁴ is selected from the group consisting of amino acids of the general formula IIIa



wherein m is an integer in the range from 1 to 3, and Y is selected from the group consisting of OH, SH, NH₂, CONH₂, COOH and OPO₃H;


and

N-substituted amino acids of the general formula IIIb



wherein m and Y are as defined above.

60 (new). A peptide according to claim 59, wherein X² is selected from L-amino acids of the general formula IIc



wherein n is 1 or 2 and R¹ is selected from the group consisting of optionally substituted five-, six- and seven-membered non-aromatic rings.

61 (new). A peptide according to claim 59, wherein X³ and X⁸ are each independently selected from the group consisting of D- and L-phenylalanine, D- and L-tryptophan, D- and L-tyrosine, D- and L-histidine, β-2-naphthyl-L-alanine, β-2-naphthyl-D-alanine, β-1-naphthyl-L-alanine, β-1-naphthyl-D-alanine, N-(2,3-dimethoxybenzyl)glycine, N-(3-indolylethyl)glycine, N-benzylglycine, -(methylnaphthalyl)glycine, N-(2,2-diphenylethyl)glycine, -(indanyl)glycine, N-(2-ethyl-2-pyridinyl)glycine and N-(4-methoxyphenylethyl)glycine.

62 (new). A peptide according to claim 59, wherein the peptide fragment is selected from the group consisting of dChaFsrYLWS, SLChaFsQYLWS, eChaFsyYLWS, DChaFsrYLWS, DChaFSrYLWS, dChaFSrYLWS, tChaFsrYLWS, dChaFsrYL²nAS, DChaFsRrYLWS, DChaFsrYL¹nAS, eChaFsYYLWS, D-Cha-F-s-r-L-L-W-h, D-Cha-F-s-r-Cha-L-W-l, D-Cha-F-s-r-Y-L-Nal-h, D-Cha-F-s-r-DMB-f-TRA-MEA, D-Cha-F-s-r-DMB-f-Bzl-MEA, D-Cha-F-s-r-DMB-f-AMN-MEA and D-Cha-F-s-r-DMB-f-DMB-l

wherein Cha designates β-cyclohexyl-L-alanine, ¹nA designates β-1-naphthyl-L-alanine, ²nA designates β-2-naphthyl-L-alanine, capital letters designate L-amino acids, lower case letters designate D-amino acids, βA designates β-alanine, DMB designates N-(2,3-dimethoxybenzyl)glycine, TRA designates N-(3-indolylethyl)glycine, MEA designates N-(2-methoxyethyl)glycine, Bzl designates N-benzylglycine and AMN designates N-(methylnaphthalyl)glycine.

63 (new). A peptide according to claim 59, which comprises more than one peptide fragment of the general formula I.

64 (new). A peptide according to claim 63, wherein each of the peptide fragments are attached to a common scaffold.

65 (new). A pharmaceutical composition comprising a peptide according to claim 59.

[illegible]

providing a modified uPAR of a non-human mammalian species, said modified uPAR being modified in a manner which renders it capable of being antagonized by a peptide antagonist according to claim 59 while retaining its capability of binding to a receptor-binding form of uPA of said mammalian species substantially unchanged,

68 (new). A method according to claim 67, wherein said model system comprises one or more of the following test systems:

- 4